WO2005068464A3 - Process for preparing tadalafil and its intermediates - Google Patents
Process for preparing tadalafil and its intermediates Download PDFInfo
- Publication number
- WO2005068464A3 WO2005068464A3 PCT/IN2004/000389 IN2004000389W WO2005068464A3 WO 2005068464 A3 WO2005068464 A3 WO 2005068464A3 IN 2004000389 W IN2004000389 W IN 2004000389W WO 2005068464 A3 WO2005068464 A3 WO 2005068464A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intermediates
- tadalafil
- preparing tadalafil
- preparing
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1270/MUM/2003 | 2003-12-15 | ||
IN1270MU2003 | 2003-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005068464A2 WO2005068464A2 (en) | 2005-07-28 |
WO2005068464A3 true WO2005068464A3 (en) | 2005-12-08 |
Family
ID=34779411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2004/000389 WO2005068464A2 (en) | 2003-12-15 | 2004-12-14 | Process for preparing tadalafil and its intermediates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005068464A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006049986A1 (en) * | 2004-10-28 | 2006-05-11 | Dr. Reddy's Laboratories Ltd. | Polymorphic forms of tadalafil |
EP1851222A1 (en) * | 2005-02-25 | 2007-11-07 | Teva Pharmaceutical Industries Ltd | Process of synthesizing tadalafil |
KR20070099035A (en) | 2005-02-25 | 2007-10-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | Tadalafil having a large particle size and a process for preparation thereof |
WO2007052283A1 (en) * | 2005-10-31 | 2007-05-10 | Alembic Limited | An improved process for preparing tadalafil and its intermediate |
US8445698B2 (en) | 2007-06-29 | 2013-05-21 | Ranbaxy Laboratories Limited | Process for the preparation of an intermediate of tadalafil |
EP2107059A1 (en) | 2008-03-31 | 2009-10-07 | LEK Pharmaceuticals D.D. | Conversion of tryptophan into ß-carboline derivatives |
WO2009144734A1 (en) * | 2008-05-28 | 2009-12-03 | Hetero Research Foundation | Process for preparation of tadalafil |
PL385356A1 (en) | 2008-06-03 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Method of tadalaphil production |
US8829023B2 (en) | 2011-02-10 | 2014-09-09 | Interquim, S.A. | Process for obtaining compounds derived from tetrahydro-β-carboline |
CN105106216A (en) * | 2015-09-11 | 2015-12-02 | 青岛蓝盛洋医药生物科技有限责任公司 | Drug tadalafil composition capsules for treating impotence of males |
CN105272981A (en) * | 2015-11-19 | 2016-01-27 | 中国药科大学 | New Tadalafil crystal form |
CN105384740A (en) * | 2015-12-18 | 2016-03-09 | 海南通用康力制药有限公司 | Tadanafil preparation intermediate high purity crystal and preparation method thereof |
CN105481860B (en) * | 2015-12-31 | 2018-03-02 | 山西普德药业有限公司 | A kind of process for refining of Tadalafei I type crystal |
CN107759592A (en) * | 2017-11-01 | 2018-03-06 | 吉林医药学院 | The preparation of tadalafil intermediate |
RU2692764C1 (en) | 2019-04-26 | 2019-06-27 | Общество с ограниченной ответственностью "Балтфарма" | Method of producing tadalafil |
CN115184531A (en) * | 2021-04-07 | 2022-10-14 | 浙江康恩贝制药股份有限公司 | Method for simultaneously determining contents of 3 impurities in tadalafil |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019978A1 (en) * | 1994-01-21 | 1995-07-27 | Laboratoires Glaxo Wellcome S.A. | Tetracyclic derivatives, process of preparation and use |
WO1996038131A1 (en) * | 1995-06-02 | 1996-12-05 | Glaxo Group Limited | Method of producing a solid dispersion of a poorly water soluble drug |
US6140329A (en) * | 1995-07-14 | 2000-10-31 | Icos Corporation | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
-
2004
- 2004-12-14 WO PCT/IN2004/000389 patent/WO2005068464A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019978A1 (en) * | 1994-01-21 | 1995-07-27 | Laboratoires Glaxo Wellcome S.A. | Tetracyclic derivatives, process of preparation and use |
WO1996038131A1 (en) * | 1995-06-02 | 1996-12-05 | Glaxo Group Limited | Method of producing a solid dispersion of a poorly water soluble drug |
US6140329A (en) * | 1995-07-14 | 2000-10-31 | Icos Corporation | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Also Published As
Publication number | Publication date |
---|---|
WO2005068464A2 (en) | 2005-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005068464A3 (en) | Process for preparing tadalafil and its intermediates | |
SG158848A1 (en) | Method for producing annelated piperazin-2-one derivatives and intermediates of said method | |
WO2007001385A3 (en) | Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | |
WO2006018220A3 (en) | Method for the production of dihydropteridinones | |
WO2006067456A3 (en) | Process for preparing rosuvastatin | |
WO2009157019A3 (en) | Process for preparing ezetimibe using novel allyl intermediates | |
WO2006052768A3 (en) | Process for preparing quinoline compounds and products obtained therefrom | |
WO2004035800A3 (en) | Intermediate cefdinir salts | |
AU2003253188A1 (en) | Novel processes and intermediates for preparing triazolo-pyridines | |
WO2005049561A3 (en) | Processes for preparing novel methylene blue derivative | |
WO2004052881A3 (en) | Process for preparing (s)-pantoprazole | |
WO2007026373A3 (en) | Process for preparing rivastigmine | |
AU2003226138A1 (en) | Process for preparing phenylorganosilicon intermediates | |
WO2005004606A3 (en) | Pyridinylanilides | |
WO2006043175A3 (en) | Process for preparing purine compounds | |
WO2002096799A3 (en) | Silicon subnitride method for production and use of said subnitride | |
WO2004096828A3 (en) | Novel method and intermediates for the preparation of 19-nor-steroid compounds | |
AU2003287844A1 (en) | Novel crystalline forms of entacapone, and production thereof | |
WO2004018466A3 (en) | A method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | |
WO2004011449A3 (en) | Method for the production of phenylalanine derivatives | |
AU2003295110A1 (en) | Production process of gamma-cyhalothrin | |
WO2005023758A3 (en) | Process for the preparation of losartan potassium form i | |
AU2003254450A1 (en) | Process for preparing of paclitaxel | |
AU2003304484A1 (en) | Improved process for the preparation of intermediates useful for the preparation of zonisamide | |
WO2005021504A3 (en) | New crystalline forms of carvedilol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |